Taltz® (ixekizumab)
Effective 02/20/19

Plan	☒ MassHealth ☐Commercial/Exchange	**Program Type**	☒ Prior Authorization ☐ Quantity Limit ☐ Step Therapy
Benefit	☒ Pharmacy Benefit ☐ Medical Benefit (NLX)		
Specialty Limitations	This medication has been designated specialty and must be filled at a contracted specialty pharmacy.		
Contact Information	**Specialty Medications**		
	All Plans	Phone: 866-814-5506	Fax: 866-249-6155
	Non-Specialty Medications		
	MassHealth	Phone: 877-433-7643	Fax: 866-255-7569
	Commercial	Phone: 800-294-5979	Fax: 888-836-0730
	Exchange	Phone: 855-582-2022	Fax: 855-245-2134
	Medical Specialty Medications (NLX)		
	All Plans	Phone: 844-345-2803	Fax: 844-851-0882
Exceptions	N/A		

Overview

Taltz® (ixekizumab) is a humanized interleukin-17A antagonist indicated for the treatment of adults with:

1. Moderate-to-severe plaque psoriasis who are candidates forsystemic therapy or phototherapy
2. Active psoriatic arthritis
3. Active ankylosing spondylitis

Coverage Guidelines

Approval will be granted if the member meets the following diagnosis specific criteria:

Moderate to severe plaque psoriasis

1. Member has a diagnosis of moderate-severe plaque psoriasis **AND**
2. Member is at least 18 years of age **AND**
3. Prescriber has provided documentation of ONE of the following:
    a. Inadequate response, adverse reaction, or contraindication to at least TWO conventional therapies in any one of the following combinations (combinations DO NOT have to be used concurrently):
        i. 1 topical agent + 1 systemic agent
        ii. 1 topical agent + 1 phototherapy (required for diagnosis of guttate psoriasis)
        iii. 1 systemic agent + 1 phototherapy
        iv. 2 systemic agents
    b. Contraindication to ALL conventional therapies
        i. Topical agents
        ii. Phototherapy
        iii. Systemic agents
    c. Inadequate response or adverse reaction to ONE biologic DMARD that is FDA-approved

for plaque psoriasis

AND

4. Dosing is appropriate (see appendix)

Psoriatic arthritis

1. Member has a diagnosis of psoriatic arthritis **AND**
2. Member is at least 18 years of age **AND**
4. Prescriber has provided documentation of ONE of the following:
    a. Inadequate response, adverse reaction, or contraindication to at least ONE traditional DMARD (hydroxychloroquine, methotrexate, sulfasalazine)
    b. Inadequate response or adverse reaction to ONE biologic DMARD that is FDA-approved for the requested indication

AND

5. Dosing is appropriate (see appendix)

Continuation of Therapy

Reauthorization requires physician documentation indicating a positive response to therapy.

Limitations

1. Initial approvals will be varied based on the treatment:
    a. For moderate to severe plaque psoriasis, approvals will be granted for 3 months.
    b. For posiratic arthritis, approvals will be granted for 6 months.
2. Reauthorizations will be granted for 12 months.

Appendices

Dosing

Taltz® (ixekizumab)	**Plaque Psoriasis:** SQ: 160 mg initially at week 0, followed by 80 mg at weeks 2, 4, 6, 8, 10 and 12; followed by 80 mg every four weeks **Psoriatic Arthritis:** SQ: 160 mg initially at week 0, followed by 80 mg every 4 weeks. For psoriatic arthritis patients with coexistent moderate-to-severe plaque psoriasis, use the dosing regimen for plaque psoriasis

References

1. Taltz (ixekizumab) [prescribing information]. Indianapolis, IN: Eli Lilly and Co; May 2018
2. Nash P, Kirkham B, Okada M, et al. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. Lancet 2017; 389:2317.
3. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 4: Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol. 2009; 61:451-485.

4. Griffiths CE, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phases 3 randomised trials. Lancet. 2015;386(9993):541-51.
5. Gossec L, Smolen JS, Ramiro S, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis. 2016;75(3):499-510.
6. McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386(9999):1137-46.

Review History

11/28/16 – Reviewed
02/27/17 – Adopted SGM & ST
03/20/17 – Effective
03/01/18 – Adopted MH RS
02/20/19 – Reviewed in P&T Meeting

Disclaimer

AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.